Open, Single Arm Trial of Erlotinib As the 2Nd/3Rd Line Treatment in Advanced or Recurrent Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Wild Type and C-Met Negative Expression (Ml28941, C-Tong 1306)
2013 ◽
Vol 31
(8)
◽
pp. 1061-1069
◽
2016 ◽
Vol 310
◽
pp. 140-149
◽
2015 ◽
Vol 12
(12)
◽
pp. 4466-4477
◽
2007 ◽
Vol 13
(5)
◽
pp. 1540-1551
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 8048-8048
◽